Imipramine-induced cardiac depression is responsible for the increase in intracellular magnesium and the activation of ERK 1/2 in rats.

abstract：:Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and th...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wolbrette DL,Hussain S,Maraj I,Naccarelli GV

更新日期：2019-01-01 00:00:00

abstract：:Data obtained in both preclinical models and humans have revealed that the favorable cardiac consequences of ischemic conditioning extend beyond a direct effect on the cardiomyocyte. In the current review, we summarize our as-yet limited understanding of the complex relationships between ischemic conditioning, platele...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Przyklenk K,Whittaker P

更新日期：2017-09-01 00:00:00

abstract：BACKGROUND:The administration of aspirin is traditionally discontinued prior to coronary artery bypass grafting (CABG), given a potential risk of excessive postoperative bleeding. Few studies have previously suggested the benefits of continuing aspirin until the time of surgery. The primary aim of this review is to eva...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ma X,Ma C,Yun Y,Zhang Q,Zheng X

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:CVT-510, N-(3(R)-tetrahydrofuranyl)-6-aminopurine riboside, is a selective A(1)-adenosine receptor agonist with potential potent antiarrhythmic effects in tachycardias involving the atrioventricular (AV) node. This study, the first in humans, was designed to determine the effects of CVT-510 on AV nodal condu...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lerman BB,Ellenbogen KA,Kadish A,Platia E,Stein KM,Markowitz SM,Mittal S,Slotwiner DJ,Scheiner M,Iwai S,Belardinelli L,Jerling M,Shreeniwas R,Wolff AA

更新日期：2001-07-01 00:00:00

abstract：:Approximately 40% of heart attack survivors remain at increased risk of recurrent cardiovascular events, despite the current treatment options showing that atherothrombosis is not exclusively a disorder of lipoprotein aggregation in the arterial wall. Clinical and experimental data suggest that inflammation plays an i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kottoor SJ,Arora RR

更新日期：2018-11-01 00:00:00

abstract：:BACKGROUND: Acute myocarditis can progress to chronic heart muscle disease and cardiomyopathy. In the coxsackievirus B(3) (CB(3)) mouse model of myocarditis, early administration of captopril, an angiotensin-converting enzyme (ACE) inhibitor, ameliorated histopathological changes in inflammation, necrosis, and calcifi...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Reyes MP,Khatib R,Khatib G,Ho KL,Smith F,Kloner RA

更新日期：1998-01-01 00:00:00

abstract：BACKGROUND:Brief periods of reocclusion (postconditioning) during early reperfusion reduce myocardial infarct size. Whether postconditioning has an effect on lethal ventricular arrhythmias independent of infarction in an in-vivo regional ischemia model is unknown. The purpose of this study was to determine if postcondi...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kloner RA,Dow J,Bhandari A

更新日期：2006-03-01 00:00:00

abstract：BACKGROUND:Congestion predominates in exacerbations of heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), but evidence suggests that excess volume may be distributed differently in these 2 subgroups. METHODS AND RESULTS:In this retrospective study, diuretic efficiency (DE, or ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Broscious R,Kukin A,Noel ZR,Devabhakthuni S,Seung H,Ramani GV,Reed BN

更新日期：2021-03-01 00:00:00

abstract：:Phosphodiesterase inhibitors as inodilators in heart failure are associated with promotion of arrhythmias. Calcium sensitizers have been proposed for the treatment of severe decompensated heart failure. The effect of levosimendan, a calcium sensitizer, and milrinone, a phosphodiesterase inhibitor, on ventricular arrhy...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Papp JG,Pollesello P,Varró AF,Végh AS

更新日期：2006-06-01 00:00:00

abstract：:Nonvalvular atrial fibrillation (AF) confers an increased risk of thromboembolism, with a 5-fold higher risk of ischemic stroke. Oral anticoagulation (OAC) has shown to be highly effective in preventing stroke and mortality compared to placebo and is also used in patients without AF for both treatment and prophylaxis ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gallego P,Roldán V,Lip GY

更新日期：2014-01-01 00:00:00

abstract：:BACKGROUND: Nicotine, the active agent in tobacco, is released into the circulation during cigarette smoking. It elevates plasma catecholamines, heart rate, and arterial blood pressure; produces coronary spasm; and increases myocardial work and oxygen demand with concomitant reduction in oxygen supply. This may genera...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Mehta MC,Jain AC,Mehta A,Billie M

更新日期：1997-10-01 00:00:00

abstract：OBJECTIVE:Acute lung injury is a common complication after cardiopulmonary bypass (CPB). Oxidative damage greatly impacts CPB-induced lung ischemic pathogenesis and may represent a target for treatment. We aimed to investigate whether curcumin upregulates heme oxygenase 1 (HO-1) expression and ameliorates lung injury i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Liu K,Chen HL,Huang H,Jing H,Dong GH,Wu HW,You QS

更新日期：2012-12-01 00:00:00

abstract：:A large body of evidence indicates that a persistently high heart rate is associated with a significant risk for higher mortality and sudden death in individuals with a variety cardiovascular disorders, as well as in the general population. Heart rates elevated beyond a certain threshold have been found to be a risk f...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Singh N

更新日期：2002-04-01 00:00:00

abstract：:BACKGROUND: Circulating cells influence myocardial function during ischemia and reperfusion, (eg, neutrophils exacerbate, and platelets protect the myocardium from deterioration). This study was designed to determine the role of red blood cells on myocardial function following ischemia and reperfusion in isolated rat ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Yang BC,Nichols WW,Mehta JL

更新日期：1996-10-01 00:00:00

abstract：BACKGROUND:The oral vasopressin-2 receptor antagonist, tolvaptan, causes aquaresis and improves symptoms in patients with congestive heart failure. However, few studies have explored the effect of tolvaptan in acute heart failure (AHF) patients ≥90 years old. METHODS:This study enrolled 106 AHF patients treated with t...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sato Y,Uzui H,Mukai M,Shiomi Y,Hasegawa K,Ikeda H,Tama N,Fukuoka Y,Morishita T,Ishida K,Kaseno K,Miyazaki S,Nakano A,Tada H

更新日期：2020-01-01 00:00:00

abstract：:Congestive heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with more than 290 000 deaths in the United States each year. Recent advances in heart failure therapy target many of the mechanical and structural aspects of heart failure...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Thompson KA,Philip KJ,Barbagelata A,Schwarz ER

更新日期：2010-06-01 00:00:00

abstract：:BACKGROUND: Digoxin improves baroreflex function and reduces neurohumoral activation in severe heart failure, but it is uncertain how digoxin affects ventricular remodeling and progression to left ventricular dysfunction. In addition, the effect of digoxin in in vitro beta-adrenoceptor density and function, and contra...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sullebarger JT,D'Ambra PM,Clark LC,Thanikarry L,Fontanet HL

更新日期：1998-10-01 00:00:00

abstract：:Acute medical illnesses are associated with a prolonged elevation in inflammatory markers that predisposes patients to thrombosis beyond the duration of their hospital stay. In parallel, both observational and randomized data have demonstrated a rate of postdischarge venous thromboembolic events that often exceeds tha...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Korjian S,Daaboul Y,Halaby R,Goldhaber SZ,Cohen AT,Singh K,Susheela AT,Harrington RA,Hull RD,Hernandez AF,Gibson CM

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Myocardial infarction causes the acidification of the cellular environment and the resultant acidosis maybe arrhythmogenic. The effect of acidosis on the action of antiarrhythmic drugs, an important issue in the antiarrhythmic drug therapy after myocardial infarction, remains to be studied. METHODS:To evalu...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lin C,Ke X,Cvetanovic I,Ranade V,Somberg J

更新日期：2005-03-01 00:00:00

abstract：PURPOSE:Methotrexate is an anti-inflammatory drug that has been shown to have anti-ischemic effects. Our aim was to evaluate if methotrexate could reduce infarct size in patients with ST-segment elevation myocardial infarction (STEMI). METHODS:We randomly assigned patients with STEMI to receive either methotrexate or ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Moreira DM,Lueneberg ME,da Silva RL,Fattah T,Gottschall CAM

更新日期：2017-11-01 00:00:00

abstract：:Low-molecular-weight heparins (LMWHs) endure as important drugs for thromboprophylaxis. Although clinical use relies on the subcutaneous (SC) route, our previous studies show that single-dose orally administered LMWHs have antithrombotic activity. Since thromboprophylaxis requires long-term treatment, we examined anti...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hiebert LM

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:In recent decades, clinical trials have played an increasingly important role in determining how we practice. Trial results proving that a clinical finding poses risk have led to interventions that try to reduce risk. Clinical trials proving that a particular therapy provides better outcome than another ther...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Reiffel JA

更新日期：2000-01-01 00:00:00

abstract：:Recently, cyclooxygenase-2 (COX-2) inhibitors (coxibs), a class of drugs intended to be painkillers, have created unprecedented controversy because of their cardiovascular risk profile. The controversy has affected the patients, health-care providers, the Food and Drug Administration, and the manufacturers of these ag...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Schrör K,Mehta P,Mehta JL

更新日期：2005-06-01 00:00:00

abstract：:Cardio-Oncology has blossomed as a new field in cardiovascular medicine, in large part due to new therapies, which may have cardiovascular sequelae. Despite this, anthracyclines still serve as cornerstone therapy for most pediatric cancers, several solid tumors and hematological malignancies. Cardiotoxicity is the mai...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Screever EM,Meijers WC,Moslehi JJ

更新日期：2021-03-01 00:00:00

abstract：:The peptide hormone relaxin has traditionally been linked to the maternal adaptation of the cardiovascular system during the first trimester of pregnancy. By promoting nitric oxide formation through different molecular signaling events, relaxin has been proposed as a pleiotropic and cardioprotective hormone in the set...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Raleigh JM,Toldo S,Das A,Abbate A,Salloum FN

更新日期：2016-07-01 00:00:00

abstract：:The existing clinical studies on remote ischemic preconditioning in patients undergoing cardiovascular surgery are critically reviewed, with a focus on infarct size reduction and clinical outcome as end points. Confounders, notably the use of propofol anesthesia are identified. The need for better designed trials with...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Heusch G

更新日期：2017-07-01 00:00:00

abstract：:Effects of therapy with the potassium-channel opener and vasodilator nicorandil were studied in reperfused infarction of hypertrophied hearts by using magnetic resonance imaging (MRI), hemodynamic measurements, and histochemical staining. Aortic banding was performed on 22 Sprague-Dawley rats to induce left ventricula...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Schalla S,Higgins CB,Chujo M,Saeed M

更新日期：2004-09-01 00:00:00

abstract：:BACKGROUND: We determined if a single administration of heparin or nonanticoagulant N-acetylheparin could reduce myocardial injury resulting from a 90-minute occlusion of the left circumflex coronary artery (LCX) and 6 hours of reperfusion in the anesthetized canine. METHODS AND RESULTS: Heparin (2 mg/kg), N-acetylhep...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gralinski MR,Driscoll EM,Friedrichs GS,DeNardis MR,Lucchesi BR

更新日期：1996-07-01 00:00:00

abstract：INTRODUCTION:Pulmonary hypertension (PH) is a potentially deadly disease for infants and adults with few existing medical interventions and no cure. In PH, increased blood pressure in the pulmonary artery eventually leads to heart failure. Fasudil, an antagonist of Rho-kinase, causes vasodilation leading to decreased s...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hanson SFL,Terry MH,Moretta DT,Power GG,Wilson SM,Alam F,Ahsan F,Blood AB,Giri PC

更新日期：2018-09-01 00:00:00

abstract：:Neuropeptide Y is released together with norepinephrine from sympathetic nerve terminals during conditions of increased sympathetic activity. Neuropeptide Y is known to inhibit vagal activity, and accordingly, it might increase the risk for ventricular fibrillation during myocardial ischemia-reperfusion, with concomit...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ilebekk A,Eriksen M,Sevre K,Aspelin T,Björkman JA,Lyberg T,Nordlander M

更新日期：2006-09-01 00:00:00